Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Oct 28;122(8):895-909.
doi: 10.1017/S0007114519001715.

Iron status and inherited haemoglobin disorders modify the effects of micronutrient powders on linear growth and morbidity among young Lao children in a double-blind randomised trial

Affiliations
Randomized Controlled Trial

Iron status and inherited haemoglobin disorders modify the effects of micronutrient powders on linear growth and morbidity among young Lao children in a double-blind randomised trial

Sonja Y Hess et al. Br J Nutr. .

Abstract

Some studies found that providing micronutrient powder (MNP) causes adverse health outcomes, but modifying factors are unknown. We aimed to investigate whether Fe status and inherited Hb disorders (IHbD) modify the impact of MNP on growth and diarrhoea among young Lao children. In a double-blind controlled trial, 1704 children of age 6-23 months were randomised to daily MNP (with 6 mg Fe plus fourteen micronutrients) or placebo for about 36 weeks. IHbD, and baseline and final Hb, Fe status and anthropometrics were assessed. Caregivers provided weekly morbidity reports. At enrolment, 55·6 % were anaemic; only 39·3 % had no sign of clinically significant IHbD. MNP had no overall impact on growth and longitudinal diarrhoea prevalence. Baseline Hb modified the effect of MNP on length-for-age (LAZ) (P for interaction = 0·082). Among children who were initially non-anaemic, the final mean LAZ in the MNP group was slightly lower (-1·93 (95 % CI -1·88, -1·97)) v. placebo (-1·88 (95 % CI -1·83, -1·92)), and the opposite occurred among initially anaemic children (final mean LAZ -1·90 (95 % CI -1·86, -1·94) in MNP v. -1·92 (95 % CI -1·88, -1·96) in placebo). IHbD modified the effect on diarrhoea prevalence (P = 0·095). Among children with IHbD, the MNP group had higher diarrhoea prevalence (1·37 (95 % CI 1·17, 1·59) v. 1·21 (95 % CI 1·04, 1·41)), while it was lower among children without IHbD who received MNP (1·15 (95 % CI 0·95, 1·39) v. 1·37 (95 % CI 1·13, 1·64)). In conclusion, there was a small adverse effect of MNP on growth among non-anaemic children and on diarrhoea prevalence among children with IHbD.

Trial registration: ClinicalTrials.gov NCT02428647.

Keywords: Anaemia; Diarrhoea; Growth; Inherited Hb disorder; Iron status; Micronutrient powder; Young children.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow chart of study participants. * The main trial included four intervention groups; only two of these are included in the present analysis, for which details are shown here. MNP, micronutrient powder; IHbD, inherited Hb disorders.
Fig. 2
Fig. 2
Effect modification of baseline anaemia and iron status on Hb and iron status at end line among young children who received either a low-iron-, high-zinc-containing micronutrient powder (▪) or a placebo powder (◻). Only selected significant or marginally significant effect modifications are shown; a complete overview of effect modifications is included in Table 4. Iron status indicators adjusted for inflammation. Continuous outcomes log transformed for analysis. sTfR, soluble transferrin receptor. Values are means, with standard deviations represented by vertical bars.
Fig. 3
Fig. 3
Effect modification of inherited Hb disorder (IHbD) on final iron status among young children who received either a low-iron, high-zinc micronutrient powder (◻) or a placebo powder (◻). Only significant or marginally significant effect modifications are shown; a complete overview of effect modifications is included in Table 4. Iron status indicators adjusted for inflammation. Continuous outcomes log transformed for analysis. All IHbD were combined into one category and compared against all cases without clinically significant IHbD. sTfR, soluble transferrin receptor. Values are means, with standard deviations represented by vertical bars.
Fig. 4
Fig. 4
Effect modification of inherited Hb disorder (IHbD) and baseline anaemia on selected growth outcomes among young children who received either a low-iron-, high-zinc-containing micronutrient powder (◻) or a placebo powder (◻). Only selected significant or marginally significant effect modifications are shown; a complete overview of effect modifications is included in Table 4. All IHbD were combined into one category (i.e. α- or β-thalassaemia or Hb E) and compared against all cases without clinically significant IHbD. WLZ, weight-for-length z score; LAZ, length-for-age z score; MUAC, mid-upper arm circumference; MUACZ, mid-upper arm circumference z score. Values are means, with standard deviations represented by vertical bars.

References

    1. Black RE, Victora CG, Walker SP, et al. (2013) Maternal and child undernutrition and overweight in low-income and middle-income countries. Lancet 382, 427–451. - PubMed
    1. World Health Organization (2016) WHO Guideline: Multiple Micronutrients Powders for Point-of-use Fortification of Foods Consumed by Children 6-23 Months of Age and Children Aged 2-12 Years. Geneva, Switzerland: World Health Organization.
    1. De-Regil LM, Jefferds MED & Pena-Rosas JP (2017) Point-of-use fortification of foods with micronutrient powders containing iron in children of preschool and school-age. Cochrane Database Syst Rev, issue 11, CD009666. - PMC - PubMed
    1. Salam RA, Macphail C, Das JK, et al. (2013) Effectiveness of Micronutrient Powders (MNP) in women and children. BMC Public Health 13, Suppl. 3, S22. - PMC - PubMed
    1. Pasricha SR & Drakesmith H (2016) Iron deficiency anemia: problems in diagnosis and prevention at the population level. Hematol Oncol Clin North Am 30, 309–325. - PubMed

Publication types

MeSH terms

Associated data